Preview

Bulletin of the Medical Institute "REAVIZ" (REHABILITATION, DOCTOR AND HEALTH)

Advanced search

Radiation therapy for recurrence of rhabdomyosarcoma of the parotid salivary gland after surgical removal (clinical case)

https://doi.org/10.20340/vmi-rvz.2024.6.CASE.4

Abstract

Relevance. The treatment of soft tissue sarcomas, a rare and diverse type of cancer, requires an integrated approach that involves a multidisciplinary team of specialists. Surgical removal of the primary tumor is recommended in specialized centers after a thorough diagnosis and development of an individualized treatment plan. It is crucial to assess the risk of local recurrence even before surgery and to ensure continuity of care for patients who undergo non-curative operations. Radio- and chemoresistance in sarcomas limits the effectiveness of radiation therapy and chemotherapy, and delays in initiating treatment can worsen the prognosis. However, modern radiotherapy equipment and techniques for reducing radiation doses allow us to overcome resistance in malignant cells and reduce tumor size.
Description of the clinical case. A patient with a suspected malignant neoplasm of the right parotid salivary gland underwent surgery, according to the results of the histological examination, and a carcinosarcoma of the salivary gland G3 (pT2N0M0) was confirmed. However, the edge of the resection was not indicated. One month after the surgical removal of the tumor, the patient experienced a local recurrence of the disease. However, they did not receive any further antitumor treatment at that time. Only one year later, they were admitted to an oncological clinic, where they received palliative radiation therapy after verification of the local relapse and consultation with the federal center. The irradiation was carried out in two stages: multifractionated hypofractional irradiation in a single dose of 3.7 Gy twice a day for a total dose of 19 isoGy, followed by a 3-week break and daily hypofractionated irradiation in a single dose of 3 Gy for a total of 61 Gy. Against the background of treatment, we were able to achieve a reduction in tumor mass by 85% compared to the initial size. We also saw a reduction in pain and an improvement in the general somatic status and quality of life of the patient. Unfortunately, this positive response was short-lived due to the aggressiveness of the histological form of the disease. In this clinical case, surgery to remove the residual tumor was not performed.
Conclusion. Hypofractionated radiation therapy is an effective treatment option for recurrent rhabdomyosarcoma in the parotid salivary gland, as it allows for a significant reduction in tumor formation. However, due to its biological characteristics and aggressive nature, it requires continuous and urgent comprehensive treatment.

About the Authors

D. V. Chernyaev
Krasnoyarsk State Medical University named after Professor V.F. Voyno-Yasenetsky; Krasnoyarsk Regional Clinical Oncology Dispensary named after A.I. Kryzhanovsky
Russian Federation

Denis V. Chernyaev, Assistant of the Department of Oncology and Radiation Therapy with a Course of Postgraduate Education; oncologist-radiotherapist 

Partizana-Zheleznyaka St., 1, Krasnoyarsk, 660022;
1-ya Smolenskaya St., 16, Krasnoyarsk, 660133


Competing Interests:

The authors declare no competing interests.



E. V. Galimov
Krasnoyarsk Regional Clinical Oncology Dispensary named after A.I. Kryzhanovsky
Russian Federation

Evgeniy V. Galimov, Oncologist-radiotherapist 

1-ya Smolenskaya St., 16, Krasnoyarsk, 660133


Competing Interests:

The authors declare no competing interests.



V. A. Kozin
Krasnoyarsk State Medical University named after Professor V.F. Voyno-Yasenetsky; Krasnoyarsk Regional Clinical Oncology Dispensary named after A.I. Kryzhanovsky
Russian Federation

Valeriy A. Kozin, Assistant of the Department of Oncology and Radiation Therapy with a Course of Postgraduate Education; Head of the Day Hospital of Radiotherapy 

Partizana-Zheleznyaka St., 1, Krasnoyarsk, 660022;
1-ya Smolenskaya St., 16, Krasnoyarsk, 660133


Competing Interests:

The authors declare no competing interests.



R. A. Zukov
Krasnoyarsk State Medical University named after Professor V.F. Voyno-Yasenetsky; Krasnoyarsk Regional Clinical Oncology Dispensary named after A.I. Kryzhanovsky
Russian Federation

Ruslan A. Zukov, Dr. Sci. (Med.), Professor, Head of the Department of Oncology and Radiation Therapy with a Course of Postgraduate Education; Chief Physician 

Partizana-Zheleznyaka St., 1, Krasnoyarsk, 660022;
1-ya Smolenskaya St., 16, Krasnoyarsk, 660133


Competing Interests:

The authors declare no competing interests.



E. V. Semenov
Krasnoyarsk State Medical University named after Professor V.F. Voyno-Yasenetsky; Krasnoyarsk Regional Clinical Oncology Dispensary named after A.I. Kryzhanovsky
Russian Federation

Eduard V. Semenov, Cand. Sci. (Med.), Associate Professor of the Department of Oncology and Radiation Therapy with a Course of Postgraduate Education; Deputy Chief Physician for Outpatient Care, Head of the Outpatient Clinic 

Partizana-Zheleznyaka St., 1, Krasnoyarsk, 660022;
1-ya Smolenskaya St., 16, Krasnoyarsk, 660133


Competing Interests:

The authors declare no competing interests.



References

1. Fletcher C.D.M., Bridge J.A., Hogendoorn P.C.W., Mertens F., editors. WHO Classification of Tumours of Soft Tissue and Bone. 4th ed. IARC; Lyon, France: 2013.

2. Kaprin A.D., Starinsky V.V., Shakhzadova A.O. The state of oncological care for the population of Russia in 2023. Moscow: P.A. Herzen Moscow Oncology Research Institute − branch of the National Medical Research Center of Radiology of the Ministry of Health of Russia, 2024. (In Russ).

3. Blay JY, Soibinet P, Penel N, et al. Improved survival using specialized multidisciplinary board in sarcoma patients. Ann Oncol. 2017. Nov 1;28(11):2852–2859.

4. Aliev M.D., Bokhan B.Yu., Burov D.A. Prognostic role of resection margin in surgery of soft tissue sarcomas. Bone, soft tissue sarcomas and skin tumors. 2013;1:60-66. (In Russ).

5. Serletti J.M., Carras A.J., O’Keefe R.J., Rosier R.N. Functional outcome after soft-tissue reconstruction for limb salvage after sarcoma surgery. Plast. Reconstr. Surg. 1998;102:1576–1583. https://doi.org/ 10.1097/00006534-199810000-00036

6. Albertsmeier M, Rauch A, Roeder F, et al. External Beam Radiation Therapy for Resectable Soft Tissue Sarcoma: A Systematic Review and Meta-Analysis. Ann Surg Oncol. 2018;25(3):754–767.

7. Yang G, Yuan Z, Ahmed K, et al. Genomic identification of sarcoma radiosensitivity and the clinical implications for radiation dose personalization. Transl Oncol. 2021;14:101165.

8. Jang S.Y., Liu H.H., Mohan R. Underestimation of low-dose radiation in treatment planning of intensity-modulated radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 2008;71:1537–1546. https://doi.org/ 10.1016/j.ijrobp.2008.04.014

9. Haas R.L.M., Delaney T.F., O’Sullivan B., Keus R.B., Le Pechoux C., Olmi P., Poulsen J.-P., Seddon B., Wang D. Radiotherapy for management of extremity soft tissue sarcomas: Why, when, and where? Int. J. Radiat. Oncol. Biol. Phys. 2012;84:572–580. https://doi.org/ 10.1016/j.ijrobp.2012.01.062

10. Ministry of Health of the Russian Federation. Clinical guidelines "Soft tissue sarcomas" 2022. URL: https://cr.minzdrav.gov.ru/schema/515_2

11. Albertsmeier M., Rauch A., Roeder F., Hasenhütl S., Pratschke S., Kirschneck M., Gronchi A., Jebsen N.L., Cassier P.A., Sargos P., et al. External Beam Radiation Therapy for resectable Soft Tissue Sarcoma: A systematic review and meta-analysis. Ann. Surg. Oncol. 2018;25:754–767. https://doi.org/ 10.1245/s10434-017-6081-2

12. Folkert M.R., Singer S., Brennan M.F., Kuk D., Qin L.X., Kobayashi W.K., Cragi A.M., Alektiar K.M. Comparison of local recurrence with conventional and intensity-modulated radiation therapy for primary soft-tissue sarcomas of the extremity. J. Clin. Oncol. 2014;32:3236–3241. https://doi.org/ 10.1200/JCO.2013.53.9452

13. Bentz B.G., Singh B., Woodruff J., Brennan M., Shah J.P., Kraus D. Head and neck soft tissue sarcomas: A multivariate analysis of outcomes. Ann. Surg. Oncol. 2004;11:619–628. https://doi.org/ 10.1245/ASO.2004.03.006

14. Mattavelli D., Miceli R., Radaelli S., Mattavelli F., Cantu G., Barisella M., Quattrone P., Stacchiotti S., Sangalli C., Casali P.G., et al. Head and neck soft tissue sarcomas: Prognostic factors and outcome in a series of patients treated at a single institution. Ann. Oncol. 2013;24:2181–2189. https://doi.org/ 10.1093/annonc/mdt126

15. Eeles R.A., Fisher C., A’Hern R.P., Robinson M., Rhys-Evans P., Henk J.M., Archer D., Harmer C.L. Head and neck sarcomas: Prognostic factors and implications for treatment. Br. J. Cancer. 1993;68:201–207. https://doi.org/ 10.1038/bjc.1993.314

16. Le Vay J., O’Sullivan B., Catton C., Cummings B., Fornasier V., Gullane P., Simm J. An assessment of prognostic factors in soft-tissue sarcoma of the head and neck. Arch. Otolaryngol. Head. Neck Surg. 1994;120:981–986. https://doi.org/ 10.1001/archotol.1994.01880330061011

17. Willers H., Hug E.B., Spiro I.J., Efird J.T., Rosenberg A.E., Wang C.C. Adult soft tissue sarcomas of the head and neck treated by radiation and surgery or radiation alone: Patterns of failure and prognostic factors. Int. J. Radiat. Oncol. Biol. Phys. 1995;33:585–593. https://doi.org/ 10.1016/0360-3016(95)00256-X


Supplementary files

Review

For citations:


Chernyaev D.V., Galimov E.V., Kozin V.A., Zukov R.A., Semenov E.V. Radiation therapy for recurrence of rhabdomyosarcoma of the parotid salivary gland after surgical removal (clinical case). Bulletin of the Medical Institute "REAVIZ" (REHABILITATION, DOCTOR AND HEALTH). 2024;14(6):124-130. (In Russ.) https://doi.org/10.20340/vmi-rvz.2024.6.CASE.4

Views: 105


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2226-762X (Print)
ISSN 2782-1579 (Online)